Tg Therapeutics (TGTX) Retained Earnings (2010 - 2026)

Tg Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$1.1 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 26.67% year-over-year to -$1.1 billion; the TTM figure through Mar 2026 stood at -$1.1 billion (up 26.67% YoY), while the FY2025 annual figure was -$1.1 billion, up 29.24% from the prior year.
• Retained Earnings was -$1.1 billion for Q1 2026 at Tg Therapeutics, down from -$1.1 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$1.1 billion in Q4 2025 to a low of -$1.6 billion in Q2 2023.
• Historically, Retained Earnings has averaged -$1.4 billion across 5 years, with a median of -$1.5 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings slumped 30.69% in 2022, then climbed 29.24% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$1.5 billion in 2022, then slipped by 1.67% to -$1.6 billion in 2023, then climbed by 1.51% to -$1.5 billion in 2024, then gained by 29.24% to -$1.1 billion in 2025, then slipped by 1.66% to -$1.1 billion in 2026.
• The last three Retained Earnings figures came in at -$1.1 billion (Q1 2026), -$1.1 billion (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.